Prolonged pretreatment with carvedilol prevents 3-nitropropionic acid-induced behavioral alterations and oxidative stress in rats

Pharmacological Reports

Volumn 60, Issue 5, 2008, Pages 706-715

  Kumar, Puneet ^a   Kumar, Anil ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

3 nitropropionic acid; Carvedilol; Motor activity; Oxidative stress

Indexed keywords

3 NITROPROPIONIC ACID; CARVEDILOL; GLUTATHIONE; NITRITE; SUCCINATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CHRONIC DRUG ADMINISTRATION; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVITY; LIPID PEROXIDATION; MALE; MASTICATION; MAZE TEST; MEMORY DISORDER; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; RAT; TREATMENT DURATION; WEIGHT REDUCTION; WISTAR RAT;

EID: 57849091699     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Aksenov MY, Aksenova MV, Carney JM, Butterfield DA: Oxidative modification of glutamine synthetase by amyloid beta peptide. Free Radic Res, 1997, 27, 267-281.
2. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E et al.: Neuroehemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci, 1993, 13, 4181-4192.
3. Beal MF, Ferrante RI, Henshaw R, Matthews RT, Chan PH, Kowall NW, Epstein CJ, Schulz JB: 3-Nitropropionic acid neurotoxicity is attenuated in copper/zinc superoxide dismutase transgenic mice. J Neurochem, 1995, 65, 919-922.
4. Biniendra Z, Simmons C, Hussion S, Sikker W Jr, Ali SF: Effect of acute exposure to 3-NP on activities of endogenous antioxidants in the rat brain. Neurosci Lett, 1998, 251, 173-176.
5. Borlongan C, Koutouzis T, Freeman T, Hauser R, Cahill D, Sanberg P: Hyperactivity and hypoactivity in a rat model of Huntington's disease, the systemic 3-nitropropionic acid model. Brain Res Prot, 1997, 1, 253-257.
6. Browne SE, Ferrante RI, Beal MF: Oxidative stress in Huntington's disease. Brain Pathol, 1999, 9, 147-163.
7. de Quervain DJ, Aerni A, Roozendaal B: Preventive effect of β-adrenoceptor blockade on glucocortieoid-induced memory retrieval deficits. Am J Psychiatry, 2007, 164, 967-969.
8. Ellman GL: Tissue sulfhydryl groups. Arch Biochem Biophys, 1959, 82, 70-77.
9. Feuerstein GZ, Bril A, Ruffolo RR Jr: Protective effects of carvedilol in the myocardium. Am J Cardiol, 1997, 80, 41L-45L.
10. Fontaine MA, Geddes JW, Banks A, Butterfield DA: Effect of exogenous and endogenous antioxidants on 3-nitropionie acid-induced in vivo oxidative stress and striatal lesions, insights into Huntington's disease. J Neurochem, 2000, 75, 1709-1715.
11. Forster M, Dubey A, Dawson K, Stutts W, Lal H, Sohal R: Age-related losses of cognitive function and motor skins in mice are associated with oxidative protein damage in the brain. Proc Natl Acad Sci U S A, 1996, 88, 3633-3636.
12. Frautschy SA, Hu W, Kim P, Miller SA, White-Harris ME, Chu T, Cole GM: Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology. Neurobiol Aging, 2001, 22, 993-1005.
13. Geddes JW, Bondada V, Pang Z: Meehanisms of 3-nitropropionic acid toxicity. In: Mitochondrial Inhibitors and Neurodegenerative Disorders. Ed. Sanberg PR, Nishino, Borlongan CV, Humana Press, Totowa, New Jersey, 2000, 107-120.
14. Gornall AG, Bardawill CJ, David MM: Determination of serum proteins by means of the biuret reaction. J Biol Chem, 1949, 177, 751-756.
15. 15N] nitrate in biological fluids. Anal Biochem, 1982, 126, 131-138.
16. Guyot MC, Hantraye P, Dolan R, Palfi S, Maziere M, Brouillet E: Quantifiable bradykinesia, gait abnormalities, and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience, 1997, 79, 45-56.
17. Hamilton BF, Gould DH: Nature and distribution of brain lesions in rats intoxicated with 3-NP a type of hypoxic (energy deficient) brain damage. Acta Neuropathol, 1987, 72, 286-297.
18. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M et al.: Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem, 1995, 65, 2146-2156.
19. James LF, Hartley WJ, Williams MC, Van Kampen KR: Field and experimental studies in cattle and sheep poisoned by nitro-bearing astagalus or their toxins. Am J Vet Res, 1980, 41, 377-382.
20. Kumar P, Padi SSV, Naidu PS, Kumar A: Effect of resveratrol on 3-NP-induced neurotoxicity, an animal model of Huntington's disease: possible neuroprotective mechanisms. Behav Pharmacol, 2006, 17, 485-492.
21. Kumar P, Padi SSV, Naidu PS, Kumar A: Possible antioxidant and neuroprotective mechanisms of cyclooxygenase inhibitors in attenuating 3-nitropropionic acid-induced neurotoxicity. Fundam Clin Pharmacol, 2007, 21, 297-306.
22. Kumar P, Padi SSV, Naidu PS, Kumar A: Possible neuroprotective mechanisms of curcumin in attenuating 3-nitropropionic acid-induced neurotoxicity. Methods Find Exp Clin Pharmacol, 2007, 29, 1-7.
23. Ludolph AC, He F, Spencer PS, Hammerstad J, Sabri M: 3-Nitropropionic acid-exogenons animal neurotoxin and possible human striatal toxin. Can J Neurol Sci, 1991, 18, 492-498.
24. Ludolph AC, Seelig M, Ludoph A, Novitt P, Allen CA, Spencer P, Sabri MI: 3-NP deereases cellular energy levels and causes neuronal degeneration in cortical explants. Neurodegeneration, 1992, 1, 155-161.
25. Lysko PG, Lysko KA, Webb CL, Feuerstein G: Neuroprotective effects of carvedilol, a new antihypertensive at the N-methyl-D-aspartate receptor. Neurosci Lett, 1992, 148, 34-38.
26. Lysko PG, Lysko KA, Webb CL, Feuerstein G, Mason PE, Walter MF, Mason RP: Neuroprotective activities of carvedilol and a hydroxylated derivative, role of membrane biophysical interactions. Biochem Pharmacol, 1998, 56, 1645-1656.
27. Ma XL, Yue TL, Lopez BL, Barone FC, Christopher TA, Ruffolo RR Jr, Feuerstein GZ: Carvedilol, a new β-adreno-receptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. J Pharmacol Exp Ther, 1996, 277, 128-136.
28. Mandavilli BS, Boldogh I Van, Houten B: 3-Nitropropionic acid-induced hydrogen peroxide, mitochondrial DNA damage, and cell death are attenuated by Bcl-2 overexpression in PC12 cells. Brain Res Mol Brain Res, 2005, 133, 215-223.
29. Martin JB, Gunsella JF: Huntington's disease, pathogenesis and management. N Engl J Med, 1986, 315, 1267-1276.
30. Ming L: Moldy sugarcane poisoning - a case report with a brief review. Clin Toxicol, 1995, 33, 363-367.
31. Montilla P, Tunez I, Munoz MC, Salcedo M, Feijoo M, Munoz-Castaneda JR, Bujalance I: Effect of glucocorticoids on 3-nitropropionie acid-induced oxidative stress in synaptosomes. Eur J Pharmacol, 2004, 488, 19-25.
32. Naidu PS, Singh A, Kulkarni SK: Carvedilol attenuates nettroleptic-induced orofacial dyskinesia, possible antioxidant mechanisms. Br J Pharmacol, 2002, 136, 193-200.
33. Naidu PS, Singh A, Kulkarni SK: Quereetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia. Neuropharmacology, 2003, 44, 1100-1106.
34. Oliveira PJ, Bjork JA, Santos MS, Leino RL, Froberg MK, Moreno AJ, Wallace KB: Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol, 2004, 200, 159-168.
35. Oliveira PJ, Esteves T, Rolo AP, Monteiro P, Goncalves L, Palmeira CM, Moreno A J: Carvedilol, relation between antioxidant activity and inhibition of the mitochondrial permeability transition. Rev Port Cardiol, 2003, 22, 55-62.
36. Oliveira PJ, Esteves T, Rolo AP, Palmeira CM, Moreno AJ: Carvedilol inhibits the mitochondrial permeability transition by an antioxidant mechanism. Cardiovasc Toxicol, 2004, 4, 11-20.
37. Oliveira PJ, Guncalves L, Monteiro P, Providencia LA, Moreno AJ: Are the antioxidant properties of carvedilol important for the protection of cardiac mitochondria. Curr Vasc Pharmacol, 2005, 3, 147-158.
38. Padi SS, Chopra K: Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilol. Nephron, 2002, 92, 685-692.
39. Ramos BP, Colgan L, Nou E, Ovadia S, Wilson SR, Arnsten AF: The beta-1 adrenergic antagonist, betaxolol, improves working memory performance in rats and monkeys. Biol Psychiatry, 2005, 58, 894-900.
40. Rabasseda X: Carvedilol, an effective antihypertensive drug with antiischemic/antioxidant cardioprotective properties. Drugs Today (Bale), 1998, 34, 905-926.
41. Schulz JB, Henshaw DR, MacGarvey U, Beal MF: Involvement of oxidative stress in 3-nitropropionic acid neurotoxicity. Neurochem Int, 1996, 29, 167-171.
42. Singh A, Naidu PS, Gupta S, Kulkarni SK: Effect of natural and synthetic antioxidants in a mouse model of chronic fatigue syndrome. J Med Food, 2002, 5, 211-220.
43. Tsai M J, Goh CC, Wan YL, Chang C: Metabolic alterations produced by 3-nitropropionic acid in rat striata and cultured astrocytes, quantitative in vitro 1H nuclear magnetic resonance spectroscopy and biochemical characterization. Neuroscience, 1997, 79, 819-826.
44. Tunez I, Montilla P, Del Carmen MM, Feijoo M Drueker CR: Effect of transcranial magnetic stimulation on oxidative stress induced by 3-nitropropionic acid in cortical synaptosomes. Neurosci Res, 2006, 56, 91-95.
45. Tunez I, Monfilla P, Del Carmen MM, Feijoo M, Salcedo M: Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease. J Pineal Res, 2004, 37, 252-256.
46. Verma A, Kulkami SK: Evaluation of learning and memory mechanisms employing plus maze in rats and mice. Prog Neuropsychopharmacol Biol Psychiat, 1992, 16, 117-125.
47. Weller M, Paul SM: 3-Nitropropionic acid is an indirect excitotoxin to cultured cerebellar granule neurons. Eur J Pharmacol, 1993, 248, 223-228.
48. Wills ED: Mechanism of lipid peroxide formation in animal. Biochem J, 1966, 99, 667-676.
49. Yue TL, Wang X, Gu JL, Ruffolo RR Jr, Feuerstein GZ: Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J Pharmacol Exp Ther, 1995, 273, 1442-1449.